Patent application number | Description | Published |
20100184705 | Therapeutic Peptides and Vaccines - Compositions are disclosed that induce broadly HIV therapeutic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the identified peptides which compose CCR5 binding sites. Also disclosed are methods of selecting peptide sequences that are likely candidates for drugs which will offer effective treatment in such areas as Alzheimer's disease, psoriasis, multiple sclerosis and other diseases associated with the human inflammatory cascade as well as related retroviruses such as HTLV-1, the cause of tropical spastic paraparesis. | 07-22-2010 |
20100216120 | Rapid infectious virus assay - An assay to detect or quantify HIV infectious virus from clinically relevant cellular compartments, or reservoirs, in anti-retrovirally treated patients whose viral levels are low to undetectable is described. The method detects infectious virus in patients whose plasma viral loads are considered to be below the limit of current PCR based detection methods and thereby is more relevant for guiding treatment. A further advantage is that the method allows viral tropism to be directly determined in the presence of specific inhibitors of CCR5 or CXCR4. Drug sensitivity can also be directly determined without the need to laboriously recover patient virus by culture for extended time periods, a method that allows for viral selection or evolution, which is not desirable. Patient cells, like the blood mononuclear cells, or monocytes, are isolated and cultured in the presence of cytokines like CSF-1/M-CSF or GM-CSF. to promote their differentiation. Cells are activated with lectins, mitogenic antibodies, phorbol esters, Toll Receptor stimulation or inducers of NfKb or NFAT, followed by agents that induce viral release, like ATP or stimulation of autophagy with LiCl, spermidine, or rapamycin. A key aspect of the invention relates to the timing of the addition of these agents for optimal viral release. A further aspect of the invention relates to sensitive detection of released virus which can be accomplished by adding so-called reporter cells which are under control of the HIV TAT protein so that upon infection these cells synthesize proteins or enzymes that allow for the measurement of infectious particles. | 08-26-2010 |
20110152179 | Method of treating HIV in drug resistant non plasma viral reservoirs with monomeric DAPTA - Residual HIV-1 replication reemerges after intensive therapy from location or locations in the body called the drug resistant non-plasma viral reservoir. Methods are disclosed of treating HIV by inhibiting or blocking this reemergence with various monomeric therapeutic peptide compositions including monomeric DAPTA prepared in least 80% trifluoroethanol, with vigorous shaking for at least about 24 hours at about 37° C. | 06-23-2011 |
20110245180 | Modified Peptide that reduces pain in peripheral neuropathy - Chemokine signaling is important in neuropathic pain, with microglial cells expressing CCR2 playing a well established key role. DAPTA, a gp120-derived CCR5 entry-inhibitor has been shown to inhibit CCR5-mediated monocyte migration and to attenuate neuroinflammation. We disclose here that as a stabilized analog of DAPTA, the short peptide All D TTNYT exhibits potent antagonism for both CCR2 (IC | 10-06-2011 |
20140322250 | Peptides for the Treatment of Multiple Sclerosis and Related Diseases - A method of treatment of neurodegenerative illness in a patient comprising the steps of preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier. The D peptide has the general structure: A-B-C-D-E-F-G-H in which
| 10-30-2014 |
20140322251 | Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions - A method of treating a microbial inflammatory encephalopathy condition in a patient is disclosed. The method has the steps of (1) preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier and (2) administering the composition to the patient in a therapeutically effective dose. The D peptide further comprises the general structure: A-B-C-D-E-F-G-H in which:
| 10-30-2014 |
20140322252 | Peptides for Treating Alzheimers's Disease and Related Conditions - A method of treating loss of memory or motor function due to brain neurodegenerative condition, such as Alzheimer's Disease and others, comprising the steps of:
| 10-30-2014 |
20140323393 | Uses Of Peptides to Treat Brain Injury and Disease - A method of treating loss of brain function in a patient comprising the steps of preparing a composition comprising a D peptide and a pharmaceutically acceptable carrier. The D peptide has the general structure: A-B-C-D-E-F-G-H in which
| 10-30-2014 |